Dyslipidaemias
13
0
0
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
1 terminated out of 13 trials
91.7%
+5.2% vs benchmark
0%
0 trials in Phase 3/4
18%
2 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (13)
Improved Medication and Care to Achieve Lipid Targets After Carotid Surgery
Study to Test GSK256073 in Patients With Dyslipidemia
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.
Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects
GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.
Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers
A Second Study to Determine the Effect of GSK256073A on HVTs
A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers
An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation
Effect Of GW501516X On How The Heart Obtains And Uses Energy